Organization (Other)
MABXIENCE RESEARCH SL
ClinicalTrials.gov lists MABXIENCE RESEARCH SL as lead sponsor of 15 trials. It has 8 active development programs and 9 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers MABXIENCE RESEARCH SL: 15 lead-sponsored trials and 1 legal-entity registration. Part of Fresenius SE & Co. KGaA.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (26)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Arthritis, Rheumatoid | 4 |
| Neoplasm Metastasis | 2 |
| Psoriasis | 2 |
| Anemia | 1 |
| Anemia, Sickle Cell | 1 |
Showing 5 of 26 disease areas.
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 3 |
| 2022 | 3 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 1 |
| 2014 | 1 |
| 2013 | 1 |
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (8)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| EU-Opdivo® | Melanoma | Phase 3 | 1 |
| EU-Opdivo® | Neoplasm Metastasis | Phase 3 | 1 |
| MB11 (Proposed Nivolumab Biosimilar) | Melanoma | Phase 3 | 1 |
| MB11 (Proposed Nivolumab Biosimilar) | Neoplasm Metastasis | Phase 3 | 1 |
| US- sourced Opdivo® | Melanoma | Phase 3 | 1 |
Showing 5 of 8 active programs.
Approved assets (9)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| BEVACIZUMAB | 5 |
| CARBOPLATIN | 2 |
| PEMETREXED | 1 |
| RITUXIMAB | 1 |
| Calcium/Vitamin D | 1 |
Showing 5 of 9 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 100% hit target (n=9) | 30% on time (n=10) |
Journals published in (7)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| British journal of clinical pharmacology | 2 |
| Rheumatology and therapy | 2 |
| BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 1 |
| Cancer chemotherapy and pharmacology | 1 |
| Clinical therapeutics | 1 |
Showing 5 of 7 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 494 | 163 | 2025-12-16 |
Organization relationships (5)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| PRA Health Sciences | Uses vendor | 1 |
| University of Texas | Co sponsors trial with | 1 |
| Pisa® Farmacéutica | Co sponsors trial with | 1 |
| Actoverco | Co sponsors trial with | 1 |
| Laboratorios de Productos Éticos C.E.I.S.A. | Co sponsors trial with | 1 |
Latest dated events (641)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-02-13 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-02-05 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-12-29 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-02 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 641 events.
Biomarker capability evidence (63)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALK | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 63 evidence rows.
On Scientist.com
MABXIENCE RESEARCH SL is listed as a research supplier in the Scientist.com network.
Service areas
Fresenius Kabi Oncology offers development and manufacturing of active pharmaceutical ingredients, intermediates and oral & injectable finished dosage forms.
- Website
- www.fresenius-kabi-oncology.com
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Fresenius Kabi Oncology on Scientist.com
For prices, more details, or to contact Fresenius Kabi Oncology, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.